15th August, 2016. Equity investment in initial funding round, license agreement and development project. Dublin, Ireland & Durham, North Carolina, USA
GlycoSeLect Ltd, specialists in the development and production of glycoprotein separation technology, and KBI Biopharma, Inc., (KBI), a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally, have agreed to an equity investment by KBI in GlycoSeLect as well as a license to GlycoSeLect’s recombinant prokaryotic lectin (RPL) technology.
GlycoSeLect has developed a series of glycan selective RPLs and demonstrated their applicability for the purification and manufacturing of biotherapeutics.
“GlycoSeLect is delighted to announce this investment and development project with an excellent strategic partner,” said Robert Dunne, CEO of GlycoSeLect. “This partnership will further validate our RPL technology for the characterisation and purification of biotherapeutics and will help to demonstrate that our RPLs offer an innovative approach to drug product analysis and separation. We look forward to working with the KBI team on this exciting project”
”We recognize the great potential of the GlycoSeLect RPL technology,” said Dr. Prathima Acharya, Chief Business Development Officer of KBI. “We also see unique opportunities to apply the GlycoSeLect technology for innovative process solutions in several disease areas with unmet patient need.”
GlycoSeLect Ltd is an early-stage biotechnology company developing proprietary next-generation, highly specific and cost-efficient tools for the analysis, characterization and purification of biotherapeutics.Spun-out from Dublin City University in 2013, GlycoSeLect specialises in the development of RPLs; enhanced glycoselective bioaffinity proteins that enable efficient detection, analysis and selective isolation of glycosylated biomolecules. GlycoSeLect’s current family of RPLs target a range of galactose and mannose glycoprofiles and are associated with market leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness. GlycoSeLect UK Ltd was established in 2015 to support further development, provide wider geographic reach and drive commercialization.
KBI is a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. To date, KBI has helped to advance drug development programs for over 250 clients around the world. KBI offers an extensive suite of expert development and manufacturing services through an agile, science-based and customer-focused approach.
Contact details
-
- Sarah Martin-Tyrrell
-
KBI Biopharma Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
Related topics
Related news
KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Monoclonal Antibody Candidate
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Phar...
Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization challenges.
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceu...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...
KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and M...
KBI Biopharma, Inc. (KBI Biopharma), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform, that allows for optim...